Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients

HIV Medicine

Volumn 10, Issue 1, 2009, Pages 53-59

  Ryan, P ^a   Blanco, F ^a   Garcia Gasco P ^a   Garcia Merchan J A ^a   Vispo, E ^a   Barreiro, P ^a   Labarga, P ^a   Gonzalez Lahoz J ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Chronic hepatitis C; Fattyliver; HAART; HIV; Liver fibrosis; Transient elastometry; Ultrasonography

Indexed keywords

DIDANOSINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; CASE CONTROL STUDY; CAUSAL ATTRIBUTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOHYPERTROPHY; LIVER FIBROSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ULTRASOUND; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FATTY LIVER; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; LIVER CIRRHOSIS; MALE; PREDICTIVE VALUE OF TESTS; VIRAL LOAD;

EID: 58049207732     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00651.x     Document Type: Article

References (47)

1. Choi S, Diehl A. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2005; 21: 702-707.
2. Clark J, Brancati F, Diehl A. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967.
3. Amarapurkar D, Kamani P, Patel N. Prevalence of non-alcoholic fatty liver disease: Population based study. Ann Hepatol 2007; 6: 161-163.
4. Jimba S, Nakagami T, Takahashi M. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005; 22: 1141-1145.
5. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. Hepatology 2005; 42: 44-52.
6. Browning J, Szczepaniak L, Dobbins R. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40: 1387-1395.
7. Szczepaniak L, Nurenberg P, Leonard D. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: 462-468.
8. Propst A, Propst T, Judmaier G, Vogel W. Prognosis in nonalcoholic steatohepatitis. Gastroenterology 1995; 108: 1607.
9. Hultcrantz R, Glaumann H, Lindberg G, Nilsson L. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986; 21: 109-113.
10. Hilden M, Christoffersen P, Juhl E, Dalgaard J. Liver histology in a 'normal'population - examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12: 593-597.
11. Hwang S, Luo J, Chu C. Hepatic steatosis in chronic hepatitis C virus infection: Prevalence and clinical correlation. J Gastroenterol Hepatol 2001; 16: 190-195.
12. Adinolfi L, Gambardella M, Andreana A, Tripodi M, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
13. Wilkins A, Lindley R, Dourkais S, Goldin R. Surgical pathology of the liver in HIV infection. Histopathology 1991; 18: 459-464.
14. Amarapurkar A, Sangle N. Histological spectrum of liver in HIV. Autopsy study. Ann Hepatol 2005; 4: 47-51.
15. Sulkowski M, Mehta S, Torbenson M, Thomas D. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19: 585-592.
16. Marks K, Petrovic L, Talal A, Murray M, Gulick R, Glesby M. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005; 192: 1943-1949.
17. McGovern B, Ditelberg J, Taylor L. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43: 365-372.
18. Neau D, Winnock M, Castera L. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV. J Acquir Immune Defic Syndr 2007; 45: 168-173.
19. Gaslightwala I, Bini E. Impact of HIV infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006; 44: 1026-1032.
20. Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117.
21. Bani-Sadr F, Carrat F, Bedossa P et al. Hepatic steatosis in HIV-HCV coinfected patients: Analysis of risk factors. AIDS 2006; 20: 525-531.
22. Martín-Carbonero L, Soriano V. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. AIDS 2005; 19: 621-623.
23. Bondini S, Kleiner D, Goodman Z, Gramlich T, Younossi Z. Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis 2007; 11: 17-23.
24. Laurin J. Motion - all patients with NASH need to have a liver biopsy: arguments against the motion. Can J Gastroenterol 2002; 16: 722-726.
25. Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
26. Regev A, Berho M, Jeffers L et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618.
27. Janiec D, Jacobson E, Freeth A, Spaulding L, Blaszyk H. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg 2005; 15: 497-501.
28. Poynard T, Ratziu V, Charlotte F et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non-alcoholic steato-hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 34.
29. Thabut D, Naveau S, Charlotte F et al. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steatohepatitis in patients with chronic alcoholic liver disease. J Hepatol 2006; 44: 1175-1185.
30. Hepburn M, Vos J, Fillman E, Lawitz E. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: A retrospective observational study. BMC Gastroenterol 2005; 5: 14.
31. Kutcher R, Smith G, Sen F et al. Comparison of sonograms and liver histologic findings in patients with chronic hepatitis C virus infection. J Ultrasound Med 1998; 17: 321-325.
32. Chen C, Lin S, Yang C, Yeh Y, Kuo C, Nien C. The accuracy of sonography in predicting steatosis and fibrosis in chronic hepatitis C. Dig Dis Sci 2008; 53: 1699-1706.
33. Joseph A, Saverymuttu S, al-Sam S, Cook M, Maxwell J. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991; 43: 26-31.
34. Palmentieri B, de Sio I, La Mura V et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006; 38: 485-489.
35. Mathiesen U, Franzen L, Aselius H et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002; 34: 516-522.
36. Saadeh S, Younossi Z, Remer E et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.
37. Fishbein M, Castro F, Cheruku S et al. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 2005; 39: 619-625.
38. De Ledinghen V, Douvin C, Kettaneh A et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41: 175-179.
39. Loulergue P, Callard P, Bonnard P, Pialoux G. Hepatic steatosis as an emerging cause of cirrhosis in HIV-infected patients. J Acquir Immune Defic Syndr 2007; 45: 365.
40. Hadigan C, Meigs J, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with HIV infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-139.
41. Piroth L. Liver steatosis in HIV-infected patients. AIDS Rev 2005; 7: 197-209.
42. Hirche T, Ignee A, Hirche H, Schneider A, Dietrich C. Evaluation of hepatic steatosis by ultrasound in patients with chronic hepatitis C virus infection. Liver Int 2007; 27: 748-757.
43. Monto A. Hepatitis C and steatosis. Sem Gastrointest Dis 2002; 13: 40-46.
44. Yoneda M, Mawatari H, Fujita K et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371-378.
45. De Mendoza C, de Ronde A, Smolders K et al. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS Res Human Retroviruses 2004; 20: 271-273.
46. Sutinen J, Hakkinen A, Westerbacka J et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002; 16: 2183-2193.
47. Hamaguchi M, Kojima T, Itoh Y et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708-2715.